Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 12:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 13,797 matching trials from the live ClinicalTrials.gov search.
Active, not recruiting Phase 2 Interventional Results available

A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy

NCT05923866
Conditions
Multiple System Atrophy (MSA)
Interventions
ONO-2808, Placebo
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
30 Years to 80 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
30
States / cities
Fountain Valley, California • Los Angeles, California • Palo Alto, California + 23 more
Completed Phase 2 Interventional

ALTO-300 in Depression

NCT05118750
Conditions
Major Depressive Disorder
Interventions
ALTO-300 oral (PO) tablet
Drug
Lead sponsor
Alto Neuroscience
Industry
Eligibility
18 Years to 74 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
11
States / cities
Culver City, California • Sacramento, California • Santee, California + 8 more
Withdrawn No phase listed Observational Accepts healthy volunteers

Deep Lamellar Endothelial Keratoplasty: Small Incision Technique

NCT00345020
Conditions
Corneal Transplantation
Interventions
Deep Lamellar Endothelial Keratoplasty: Small Incision Technique
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years to 95 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Brain and Central Nervous System Tumors
Interventions
tipifarnib
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Bethesda, Maryland + 8 more
Completed Phase 4 Interventional Results available

Study Using Pregnenolone to Treat Bipolar Depression

NCT01409096
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Pregnenolone, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Intubation; Difficult or Failed, Intubation Complication, Hemodynamic Instability, Critical Illness
Interventions
Delphi procedure
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions
Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa
Procedure · Drug · Biological + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 29 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
152
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more
Conditions
Biliary Tract Cancer
Interventions
CPI 613, Gemcitabine, Cisplatin
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
10
States / cities
Tucson, Arizona • Chicago, Illinois • Ann Arbor, Michigan + 7 more
Conditions
Relapsing Multiple Sclerosis
Interventions
Remibrutinib, Teriflunomide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
52
States / cities
Phoenix, Arizona • Tucson, Arizona • Fort Smith, Arkansas + 47 more
Completed Not applicable Interventional Accepts healthy volunteers Results available

New Dermal Filler for Lip Augmentation

NCT03320824
Conditions
Lip Augmentation
Interventions
New Dermal Filler, Device: FDA Approved Dermal Filler
Device
Lead sponsor
Galderma R&D
Industry
Eligibility
22 Years and older
Enrollment
273 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
14
States / cities
Encino, California • San Diego, California • Solana Beach, California + 11 more
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
BBI608, Nab-paclitaxel, Gemcitabine, Oxaliplatin, Leucovorin, Irinotecan, Fluorouracil, MM-398
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
12
States / cities
Phoenix, Arizona • Atlanta, Georgia • Fort Wayne, Indiana + 9 more
Conditions
Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelodysplastic Syndrome
Interventions
VCL-CB01, Phosphate-buffered Saline (PBS)
Biological · Other
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
22
States / cities
Tucson, Arizona • Duarte, California • Denver, Colorado + 17 more
Conditions
Opiate Dependence
Interventions
Medisorb naltrexone 380 mg
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Colton, California • Oceanside, California • Lauderhill, Florida + 7 more
Conditions
Cancer, Non-small-cell Lung Cancer, Colorectal Cancer, Papillary Thyroid Cancer, Melanoma
Interventions
XL281, famotidine
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
6
States / cities
Scottsdale, Arizona • Tampa, Florida • Detroit, Michigan + 3 more
Conditions
Hepatitis C
Interventions
Telaprevir, Ribavirin, Pegylated Interferon Alfa-2a, Highly Active Antiretroviral Therapy (HAART)
Drug · Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 65 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
46
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 42 more
Conditions
Diabetes type2, Obesity
Interventions
RESET Liner, Sham
Device · Other
Lead sponsor
Morphic Medical Inc.
Industry
Eligibility
22 Years to 65 Years
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
27
States / cities
Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more
Conditions
Acute Schizophrenia
Interventions
OPC-34712, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
674 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
19
States / cities
Little Rock, Arkansas • Springdale, Arkansas • Escondido, California + 15 more
Conditions
Hyperaldosteronism
Interventions
Not listed
Lead sponsor
University Hospital Padova
Other
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Dallas, Texas • Menomonee Falls, Wisconsin
Conditions
Acute Kidney Injury
Interventions
RMC-035, Placebo
Drug
Lead sponsor
Guard Therapeutics AB
Industry
Eligibility
18 Years to 84 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
8
States / cities
Fort Wayne, Indiana • Lincoln, Nebraska • Rochester, New York + 5 more
Conditions
Acne Vulgaris
Interventions
Olumacostat Glasaretil Gel, 5.0%, Olumacostat Glasaretil Gel, Vehicle
Drug · Other
Lead sponsor
Dermira, Inc.
Industry
Eligibility
9 Years and older
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
36
States / cities
Guntersville, Alabama • Glendale, Arizona • Bryant, Arkansas + 32 more
Not listed Phase 3 Interventional Accepts healthy volunteers

A Study of MF101 in Postmenopausal Women

NCT00906308
Conditions
Hot Flushes, Vasomotor Symptoms
Interventions
MF101 5 g/day, Placebo, MF101 10 g/day
Drug
Lead sponsor
Bionovo
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
50
States / cities
Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 44 more
Conditions
HIV-1-infection
Interventions
Bictegravir/Lenacapavir (BIC/LEN) FDC, Lenacapavir, B/F/TAF, Placebo to match B/F/TAF, Placebo to match BIC/LEN FDC, Placebo to match Lenacapavir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
51
States / cities
Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 43 more
Conditions
Arthritis, Rheumatoid
Interventions
Meloxicam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
72
States / cities
Huntsville, Alabama • Montgomery, Alabama • Anchorage, Alaska + 62 more
Conditions
Locally Advanced Pancreatic Adenocarcinoma
Interventions
Carbon Ion Radiation Therapy (CIRT), Intensity Modulated Radiation Therapy (IMRT)
Radiation
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Dallas, Texas